Newly discovered cellular pathway may lead to cancer therapies

(Baylor College of Medicine) Scientists have discovered a new cellular pathway that can promote and support the growth of cancer cells. In a mouse model of melanoma, blocking this pathway resulted in reduction of tumor growth.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Conclusion.The use of agents that act on the PD‐L1 pathway are contraindicated in the face of solid organ allografts because of unacceptably high rates of irreversible allograft rejection. It appears that the use of ipilimumab may be tolerated as the mechanism is different from that of the PD‐L1 agents.Implications for Practice.Transplant rejection is a complex process that puts stress on patients and their families and can lead to tragic results. Significant advancements in the field of immunosuppression have led to the engenderment of agents devised to extend the survival of transplant recipients. The advent of immun...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Hepatobiliary, Lung Cancer, Melanoma and Cutaneous Malignancies Immuno ‐ Oncology Source Type: research
Abstract High-throughput screening identified 5 chemical analogs (termed the WX8-family) that disrupted 3 events in lysosome homeostasis: (1) lysosome fission via tubulation without preventing homotypic lysosome fusion; (2) trafficking of molecules into lysosomes without altering lysosomal acidity, and (3) heterotypic fusion between lysosomes and autophagosomes. Remarkably, these compounds did not prevent homotypic fusion between lysosomes, despite the fact that homotypic fusion required some of the same machinery essential for heterotypic fusion. These effects varied 400-fold among WX8-family members, were time a...
Source: Autophagy - Category: Cytology Authors: Tags: Autophagy Source Type: research
Authors: Calderon-Aparicio A, Cornejo A, Orue A, Rieber M Abstract Ammonium tetrathiomolybdate (TTM) and disulfiram (DSF) are copper (Cu) chelators in cancer clinical trials partly because Cu chelation: a) restricts the activity of Cu-binding MEK1/2 enzymes which drive tumourigenesis by KRAS or BRAF oncogenic mutations and b) enhances uptake of oxaliplatin (OxPt), clinically used in advanced KRAS-mutant colorectal carcinomas (CRC). Whereas TTM decreases intracellular Cu trafficking, DSF can reach other Cu-dependent intracellular proteins. Since the use of individual or combined Cu chelation may help or interfere wi...
Source: Ecancermedicalscience - Category: Cancer & Oncology Tags: Ecancermedicalscience Source Type: research
Condition:   Cutaneous Melanoma Interventions:   Behavioral: Demographics Questionnaire;   Behavioral: Adjuvant Treatment Beliefs Scale10;   Behavioral: Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11;   Behavioral: Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13;   Beh avioral: Decisional Regret14 Sponsor:   Memorial Sloan Kettering Cancer Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We present two cases of patients with metastatic melanoma who developed secondary mitochondrial myopathy which was suspected to be induced by anti-PD1 monoclonal antibodies (mAb).
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research
Researchers at Johns Hopkins Medicine have developed a PET imaging technique...Read more on AuntMinnie.comRelated Reading: PET's view of tau could explain women's early dementia PET in the paddock New PET tracer could aid melanoma detection PET tracers help guide breast cancer therapies C-11-based PET tracer could benefit arthritis patients
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Publication date: April 2019Source: European Polymer Journal, Volume 113Author(s): Dorota Lachowicz, Alicja Karabasz, Monika Bzowska, Michał Szuwarzyński, Anna Karewicz, Maria NowakowskaAbstractThe bioconjugate of alginate and curcumin (AA-CUR) was synthesized in a simple, one-step process and used to prepare the stable calcium cross-linked spherical micelles serving as a delivery vehicle for curcumin. Above its critical micelle concentration (0.6 mg/ml) AA-CUR forms colloidally stable micelles of ca. 200 nm. Prolonged, well controlled release of curcumin was observed from the AA-CUR micelles cross-linked with calciu...
Source: European Polymer Journal - Category: Chemistry Source Type: research
TNFα mediated ceramide generation triggers cisplatin induced apoptosis in B16F10 melanoma in a PKCδ independent manner. Oncotarget. 2018 Dec 28;9(102):37627-37646 Authors: Ghosh S, Jawed JJ, Halder K, Banerjee S, Chowdhury BP, Saha A, Juin SK, Majumdar SB, Bose A, Baral R, Majumdar S Abstract Ceramide is one of the important cellular components involved in cancer regulation and exerts its pleiotropic role in the protective immune response without exhibiting any adverse effects during malignant neoplasm. Although, the PKCδ-ceramide axis in cancer cells has been an effective target in r...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Publication date: Available online 28 January 2019Source: European Polymer JournalAuthor(s): Dorota Lachowicz, Alicja Karabasz, Monika Bzowska, Michał Szuwarzyński, Anna Karewicz, Maria NowakowskaAbstractThe bioconjugate of alginate and curcumin (AA-CUR) was synthesized in a simple, one-step process and used to prepare the stable calcium cross-linked spherical micelles serving as a delivery vehicle for curcumin. Above its critical micelle concentration (0.6 mg/ml) AA-CUR forms colloidally stable micelles of ca. 200 nm. Prolonged, well controlled release of curcumin was observed from the AA-CUR micelles cross-linked with ...
Source: European Polymer Journal - Category: Chemistry Source Type: research
AbstractImmunotherapy has become the fourth cancer therapy after surgery, chemotherapy, and radiotherapy. In particular, immune checkpoint inhibitors are proved to be unprecedentedly in increasing the overall survival rates of patients with refractory cancers, such as advanced melanoma, non-small cell lung cancer, and renal cell carcinoma. However, inhibitor therapies are only effective in a small proportion of patients with problems, such as side effects and high costs. Therefore, doctors urgently need reliable predictive biomarkers for checkpoint inhibitor therapies to choose the optimal therapies. Here, we review the bi...
Source: Frontiers of Medicine - Category: General Medicine Source Type: research
More News: Baylor College of Medicine | Cancer | Cancer & Oncology | Cancer Therapy | Melanoma | Skin Cancer